Validación de Belief Medicines Questionnaire y Self-efficacy for Appropriate Medication Use Scale para medir adherencia al tratamiento farmacológico en pacientes con enfermedad inflamatoria intestinal / Validation of the Belief Medicines Questionnaire and Self-efficacy for Appropriate Medication Use Scale to measure adherence to pharmacological treatment in patients with inflammatory bowel disease

Resumen Introducción: La adherencia terapéutica es crucial en la enfermedad inflamatoria intestinal (EII) para evitar recaídas y complicaciones. En México no se dispone de una herramienta validada para evaluar adherencia en pacientes con EII. Objetivo: Traducir los instrumentos Belief Medicines Questionnaire (BMQ) y Self-Efficacy for Appropriate Medication Use Scale (SEAMS), y determinar su validez, fiabilidad y sensibilidad en pacientes mexicanos con diagnóstico de EII. Método: Se incluyeron 149 pacientes con diagnóstico de EII, previo consentimiento informado. Se tradujeron los instrumentos al español y posteriormente fueron aplicados durante la consulta médica. Para la SEAMS se realizó análisis factorial exploratorio, análisis de curva ROC y determinación del alpha de Cronbach; para el BMQ se empleó el coeficiente kappa de Cohen y su capacidad predictiva. Resultados: Se incluyeron 75 mujeres (50.3 %) con edad promedio de 44 años. La escala SEAMS mostró un único factor altamente confiable (alfa de Cronbach = 0.92) y un punto de corte de 33 para identificar a los pacientes adherentes. Las dimensiones “adherencia” y “barrera de recuerdo” del BMQ fueron adecuados predictores de adherencia. Conclusiones: Las versiones en español SEAMS y BMQ son válidas para medir autoeficacia y barreras para la adherencia al tratamiento farmacológico en pacientes mexicanos con EII.

Abstract Introduction: Treatment adherence is crucial in inflammatory bowel disease (IBD) to prevent relapses and complications. In Mexico, there is not a validated tool to assess adherence in patients with IBD. Objective: To translate the beliefs about medicines questionnaire (BMQ) and self-efficacy for appropriate medication use scale (SEAMS) instruments, as well as to determine their validity, reliability and sensitivity in IBD-diagnosed Mexican patients. Method: After informed consent was obtained, 149 IBD-diagnosed patients were included. The instruments were translated into Spanish and were subsequently applied during medical consultation. For SEAMS, exploratory factorial analysis and ROC curve analysis were carried out and Cronbach’s alpha was determined; for the BMQ, Cohen’s kappa coefficient and its predictive capacity were employed. Results: Seventy-five women (50.3%) were included, with an average age of 44 years. The SEAMS scale showed a single factor that was highly reliable (Cronbach’s alpha = 0.92) and a cutoff point of 33 to identify adherent patients. The “adherence” and “recall barrier” dimensions of the BMQ were adequate adherence predictors. Conclusions: The SEAMS and BMQ Spanish versions are valid for measuring self-efficacy and barriers to pharmacological treatment adherence in Mexican patients with IBD.